Skip to content

Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis

Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07543679
Acronym
OBSKINS
Enrollment
100
Registered
2026-04-22
Start date
2026-05-07
Completion date
2027-05-01
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D013493

Keywords

Systemic sclerosis, firmness, skin evaluation, Rodnan score, mRSS

Brief summary

Systemic sclerosis (SSc) is an autoimmune disease characterized by skin fibrosis, which clinically manifests as thickening, hardening, and loss of elasticity of the skin. Patients are typically classified as having diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc) depending on the extent of skin fibrosis. The standard assessment of cutaneous sclerosis is based on the modified Rodnan skin score (mRSS), which consists of clinical palpation of 17 areas of the body, scored from 0 (normal) to 3 (severe sclerosis) for each area, with a total of 51 points. However, the mRSS has several limitations, including high inter- and intra-observer variability, particularly depending on the clinician's experience, subjectivity of palpation with difficulties in quantifying subtle changes in firmness or elasticity, and limited sensitivity to small changes or in areas that are not severely affected. The assessment of skin fibrosis therefore faces a lack of objective, quantitative tools that are easy to use in routine clinical practice. Certain alternatives have been evaluated (durometer, ultrasound, elastography, etc.), but none has yet been fully adopted or validated for measuring firmness, elasticity, and adhesion at different depths of the skin with good accuracy and reproducibility. ADHELASKIN° technology (by Tactinnov, LTDS / École Centrale de Lyon) enables objective, highly sensitive measurement of rigidity, firmness and elasticity using an indentation method with a ruby ball sensor. The objective of our study is to assess whether the ADHELASKIN device can differentiate between the biomechanical properties of healthy patients and those of patients with SSc.

Interventions

DEVICEADHELASKIN (Tactinnov° - Ecole centrale de Lyon)

Evaluation of stiffness, elastic modulus and pile-up height for ScS patients and controls by ADHELASKIN device

Sponsors

Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients affiliated with or eligible for social security * Patients who have received informed consent about the study and have co-signed, with the investigator, a consent form to participate in the study * For case patients: Patients with SSc according to the 2013 ACR/EULAR criteria * For healthy patients: Patients without significant skin lesions who are outpatients or inpatients at a department of the Saint-Etienne University Hospital * For healthy volunteers: Volunteers without significant skin lesions who work at the Saint-Etienne University Hospital and whose participation in the study does not require any special travel

Exclusion criteria

* Persons deprived of their liberty, hospitalized without consent, hospitalized for purposes other than research; * Adults subject to legal protection measures (guardianship-curatorship) or unable to express their consent * Inflammatory or scarring dermatoses in different individuals

Design outcomes

Primary

MeasureTime frameDescription
Objectively compare skin stiffness in patients with systemic sclerosis versus healthy patientsDay 1General comparison of average stiffness values in Newtons per meter obtained using the ADHELASKIN device on all areas examined between affected and healthy patients

Secondary

MeasureTime frameDescription
Compare skin stiffness in different areas in patients with systemic sclerosis vs. healthy patientsDay 1Overall comparison of the sums and local averages and sums of the stiffness ( Newtons per meter) measured by the ADHELASKIN device on all areas explored between affected and healthy patients
Objectively compare skin elasticity in patients with systemic sclerosis vs. healthy patients.Day 1Comparison of the overall and local averages and sums of the elasticity values measured by the ADHELASKIN device in kilopascals (kPA)
Objectively compare skin firmness in patients with systemic sclerosis vs. healthy patients.Day 1Comparison of overall and local averages and sums of firmness values measured by the ADHELASKIN device in micrometers (μm)
Evaluate an association between the stiffness, elasticity, and firmness measurements obtained using the ADHELASKIN device and the mRSS score.Day 1Correlation between skin thickening measured using the mRSS score by a trained investigator and biomechanical measurements of the skin measured by ADHELASKIN
Estimate the patient experience of skin assessment using ADHELASKINDay 1Standardized patient experience questionnaire in ScS and healthy patients.
Estimate inter-investigator variability in stiffness measurement using ADHELASKINDay 1Measurement of stiffness in N/m on a small cohort of 10 patients by 2 investigators using ADHELASKIN
Compare the duration of skin stiffness measurement examinations of 17 body regions by mRSS score and using ADHELASKINDay 1Measurement of the duration of the mRSS examination on the 17 regions and using the ADHELASKIN device on these same regions on 10 patients by a trained investigator

Countries

France

Contacts

CONTACTLucile GRANGE, MD
Lucile.GRANGE@chu-st-etienne.fr(0)4 77 82 83 42
CONTACTClara PFENNINGER, PhD
clara.pfenninger@chu-st-etienne.fr(0)477120287
PRINCIPAL_INVESTIGATORLucile GRANGE, MD

Centre hospitalo-universitaire de Saint-Etienne

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026